These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 37880048)

  • 1. PARP inhibitors: A review of the pharmacology, pharmacokinetics, and pharmacogenetics.
    Zeng Y; Arisa O; Peer CJ; Fojo A; Figg WD
    Semin Oncol; 2024; 51(1-2):19-24. PubMed ID: 37880048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PARP-inhibitor potpourri: A comparative review of class safety, efficacy, and cost.
    Hennes ER; Dow-Hillgartner EN; Bergsbaken JJ; Piccolo JK
    J Oncol Pharm Pract; 2020 Apr; 26(3):718-729. PubMed ID: 31902284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The current status of PARP inhibitors in ovarian cancer.
    McLachlan J; George A; Banerjee S
    Tumori; 2016 Oct; 102(5):433-440. PubMed ID: 27716873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in Oncology.
    Bruin MAC; Sonke GS; Beijnen JH; Huitema ADR
    Clin Pharmacokinet; 2022 Dec; 61(12):1649-1675. PubMed ID: 36219340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in Development of Selective Antitumor Inhibitors That Target PARP-1.
    Liu F; Chen J; Li X; Liu R; Zhang Y; Gao C; Shi D
    J Med Chem; 2023 Dec; 66(24):16464-16483. PubMed ID: 38088333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review.
    Lau CH; Seow KM; Chen KH
    Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current status and progress in using radiolabelled PARP-1 inhibitors for imaging PARP-1 expression in tumours.
    Wang Q; Zhang J
    Eur J Med Chem; 2022 Nov; 242():114690. PubMed ID: 36041258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose Adjustment of Poly (ADP‑Ribose) Polymerase Inhibitors in Patients with Hepatic or Renal Impairment.
    Zhao D; Long X; Wang J
    Drug Des Devel Ther; 2022; 16():3947-3955. PubMed ID: 36405648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medicinal chemistry approaches of poly ADP-Ribose polymerase 1 (PARP1) inhibitors as anticancer agents - A recent update.
    Jain PG; Patel BD
    Eur J Med Chem; 2019 Mar; 165():198-215. PubMed ID: 30684797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond.
    Boussios S; Abson C; Moschetta M; Rassy E; Karathanasi A; Bhat T; Ghumman F; Sheriff M; Pavlidis N
    Drugs R D; 2020 Jun; 20(2):55-73. PubMed ID: 32215876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Review on Poly (ADP-ribose) Polymerase (PARP) Inhibitors and Synthetic Methodologies.
    Li Y; Liu CF; Rao GW
    Curr Med Chem; 2021; 28(8):1565-1584. PubMed ID: 32164505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in the Treatment of Ovarian Cancer Using PARP Inhibitors and the Underlying Mechanism of Resistance.
    Wang L; Wang Q; Xu Y; Cui M; Han L
    Curr Drug Targets; 2020; 21(2):167-178. PubMed ID: 31553293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The promising PARP inhibitors in ovarian cancer therapy: From Olaparib to others.
    Chen Y; Du H
    Biomed Pharmacother; 2018 Mar; 99():552-560. PubMed ID: 29895102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in the use of PARP inhibitor therapy for breast cancer.
    McCann KE; Hurvitz SA
    Drugs Context; 2018; 7():212540. PubMed ID: 30116283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanism and current progress of Poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancer.
    Zheng F; Zhang Y; Chen S; Weng X; Rao Y; Fang H
    Biomed Pharmacother; 2020 Mar; 123():109661. PubMed ID: 31931287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative Analyses of Poly(ADP-Ribose) Polymerase Inhibitors.
    Guha M; Sobol Z; Martin M; Hemkens M; Sung T; Rubitski E; Spellman R; Finkelstein M; Khan N; Hu W
    Int J Toxicol; 2022 Dec; 41(6):442-454. PubMed ID: 35989659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PARP Inhibitors in Ovarian Cancer.
    Mittica G; Ghisoni E; Giannone G; Genta S; Aglietta M; Sapino A; Valabrega G
    Recent Pat Anticancer Drug Discov; 2018; 13(4):392-410. PubMed ID: 29512470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PARP inhibitors as potential therapeutic agents for various cancers: focus on niraparib and its first global approval for maintenance therapy of gynecologic cancers.
    Sisay M; Edessa D
    Gynecol Oncol Res Pract; 2017; 4():18. PubMed ID: 29214031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
    Parkes EE; Kennedy RD
    Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review on mechanisms of resistance to PARP inhibitors.
    Desai C; Pathak A; Limaye S; Maniar V; Joshi A
    Indian J Cancer; 2022 Mar; 59(Supplement):S119-S129. PubMed ID: 35343196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.